Editorial: assessment of ⁶⁸Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer, a prospective single arm clinical study: California shows the way!

The article by Fendler et al. published in JAMA Oncology (1) confirms many previous studies of the prostate cancer imaging agent, 68Ga-PSMA-11 PET in the setting of biochemical recurrence (BCR). Like many before it, this study demonstrates the high sensitivity of PSMA PET/CT and PET/MR for detecting sites of disease in the post-treatment BCR setting. However, unlike almost all previous papers it is a large prospective study (n=635) conducted at two US centers (UCSF and UCLA) with carefully controlled eligibility and quality controls.